Pfizer’s stock, $PFE, remains a Hold due to significant patent expiry risk, with approximately a quarter of the company’s revenue and net income facing potential losses. This risk is a major factor in the stock’s relatively low valuation, as investors weigh the potential impact of losing exclusivity for key products against the company’s pipeline of new treatments and its diversification efforts through acquisitions like Biovac and Valneva.
Pfizer’s portfolio includes several blockbuster drugs, such as Lyrica and Ibrance, which have been major drivers of the company’s revenue in recent years. However, with patents for these drugs set to expire, the company faces significant competition from generic manufacturers, which could lead to a decline in sales. This patent expiry risk is a key concern for investors, as it could impact the company’s ability to maintain its current level of profitability. The company’s efforts to diversify its portfolio through acquisitions and development of new treatments, such as its COVID-19 vaccine, have helped to mitigate this risk to some extent.
The market has already begun to price in the potential impact of patent expiry, with $PFE trading at a relatively low valuation compared to its peers. Despite this, the company’s strong pipeline and diversification efforts have helped to support the stock, with many analysts maintaining a Hold rating. The company’s recent acquisition of Seagen has also provided a boost to its pipeline, with several promising new treatments in development. However, the patent expiry risk remains a significant concern, and investors will be closely watching the company’s progress in developing new treatments and maintaining its market share.
The patent expiry risk facing $PFE is not unique to the company, as many pharmaceutical firms face similar challenges. However, the scale of the risk is significant, with approximately 25% of the company’s revenue and net income at risk. The company’s ability to navigate this challenge will be critical to its long-term success, and investors will be closely watching its progress. The impact of patent expiry on $PFE’s financials could be significant, as seen in the following table:
| Product | Patent Expiry | 2022 Revenue |
|---|---|---|
| Lyrica | 2023 | $5.4 billion |
| Ibrance | 2027 | $4.8 billion |
Looking ahead, the key to $PFE’s success will be its ability to develop and launch new treatments to offset the impact of patent expiry. The company has a strong pipeline, with several promising new treatments in development, including its Oncology portfolio. If the company is able to successfully launch these new treatments, it could help to mitigate the impact of patent expiry and support the stock. However, if the company is unable to deliver on its pipeline, the stock could face significant downside risk.
⚡ Why it matters: The patent expiry risk facing $PFE is a significant concern for investors, as it could impact the company’s ability to maintain its current level of profitability. The company’s ability to navigate this challenge will be critical to its long-term success.
📊 By the numbers:
25% of $PFE’s revenue and net income face patent expiry risk
$5.4 billion in revenue from Lyrica in 2022
$4.8 billion in revenue from Ibrance in 2022
🔗 Source: Pfizer Investor Relations*
